24 March 2016

FIRST DENGUE VACCINE, DENGVAXIA®, AWARDED ‘THE VACCINE BREAKTHROUGH OF 2016’ AT THE 6TH ANNUAL BIOPHARMA INDUSTRY AWARDS EVENT IN SINGAPORE

Singapore – March 24, 2016 – Sanofi Pasteur, the vaccines division of Sanofi, is pleased to announce the company’s dengue vaccine, Dengvaxia®, received the award for ‘The Vaccine Breakthrough of 2016’ at the 6th annual Biopharma Industry Awards Event in Singapore.

The Biopharma Industry Awards recognize organizations and individuals for their significant contributions and achievements in Asia’s burgeoning biologics industry, as well as for their passion to better shape the global biopharmaceutical operation value chain. The award for vaccine breakthrough of the year aims to promote the production of vaccines against prevalent diseases in Asia and recognise vaccines that address a critical medical need in Asia. Criteria for choosing the winner include innovative efforts towards developing novel drugs; efforts dedicated to disease prevention and treatment in Asia; contribution to improving public health outcomes in Asia and partnerships with NGOs and country governments to improve Asia community health programs.

“This award recognizes the innovation behind Dengvaxia®, the world’s first dengue vaccine, that was developed in several endemic countries in Asia and is currently being introduced in the Philippines,”says Joselito Sta Ana, Senior Director, Regional Head Dengue, Sanofi Pasteur Asia and Japan Pacific. “Dengvaxia® was developed in close collaboration with global, regional and local public health and dengue disease experts, as well as with the healthcare and local communities of dengue-endemic countries in Asia. The vaccine has the potential to be a real game changer for dengue prevention as part of an integrated approach to managing the considerable dengue burden here in Asia, which bears 70% of the global disease burden for this debilitating disease.”

Sanofi Pasteur’s dengue vaccine, Dengvaxia®, is the world’s first vaccine licensed for the prevention of dengue caused by all four serotypes in individuals between nine and 45 years of age. To date, Dengvaxia® has received marketing approval in countries in both Latin America and Asia including Mexico, Brazil, El Salvador and the Philippines, after over two decades of research, development and clinical trials program involving over 40,000 people in 25 studies conducted in 15 countries around the world.

In the two large scale efficacy studies involving over 30,000 people from 10 endemic countries in Asia and Latin America, the Dengvaxia® vaccine documented efficacy (>65%) against all four serotypes of dengue. Furthermore, the vaccine’s major clinical benefit is likely to stem from its proven efficacy to prevent 8 out of 10 dengue hospitalizations and up to approximately 93% of severe dengue including dengue hemorrhagic fever which can be fatal amongst study participants 9 years and older.

Based on national epidemiology surveillance in several dengue-endemic countries in both Asia and Latin America, up to 70 per cent of dengue cases occur globally in those older than 9 years of age.1The potential to reduce dengue incidence in this at-risk population through vaccination should have a significant impact also on the economic burden of dengue as they represent a highly mobile and social segment of the community in dengue-endemic countries who today contribute to the spread of the disease and the considerable loss of productivity due to dengue.

The 6th annual Biopharma Industry Awards were held in conjunction with BioPharma Asia Convention 2016, the leading industry platform for pharmaceutical companies, biotechnology companies, investors and other pharma stakeholders. Award recipients receive votes from members of Asia’s life sciences community via a three-month-long nomination and voting process. Ultimately a panel of judges comprised of biopharma industry leaders select the winners among the nominees in each category.

This year, Dengvaxia® was chosen from among a prestigious list of nominees including GSK’s Rotarix® and Rabipur®, CECMED’s Heber-NASVAC and MSD’s RotaTeq®.